Central Nervous System Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 172 Patients

Artur Jurczyszyn,Jacek Czepiel,Alessandro Gozzetti,Alfonso Cerase, Hungria,E Crusoe, A L Silva,Ravi Vij,Mark A Fiala, Jo Caers,Leo Rasche,Ajay K Nooka,Sagar Lonial,David H Vesole,Sunita Philip, S Gangatharan,Agnieszka Druzdsitek,Jan Walewski,Alessandro Corso,Federica Cocito,Mariechristiane Vekemans,Erden Atilla, M S Beksac,Xavier Leleu, Jose A Davila,Ashraf Badros,Ruben Niesvizky, S Aneja,Niels Abildgaard,Efstathios Kastritis,Dorotea Fantl,Natalia Schutz,Tomas Pika,A Butrym,Magdalena Olszewskaszopa,Lidia Usnarskazubkiewicz,Norbert Grząśko,Saad Z Usmani,Hareth Nahi, Jcs Chim,Chaim Shustik, K Mądry,Suzanne Lentzsch, A świderska, Grzegorz Helbig, R Guzickakazimierczak, N Lendvain,Anders Waage,Kristian Thidemann Andersen, H Murakami,Sonja Zweegman,A B Skotnicki,Jorge J Castillo

Clinical Lymphoma, Myeloma & Leukemia（2015）

引用 1|浏览33

暂无评分

摘要

e128 The authors would like to thank Emma Landers of FireKite, an Ashfield company, part of UDG Healthcare plc, for writing support during the development of this abstract, which was funded by Millennium Pharmaceuticals, Inc. Table Best response to frontline therapy (response-evaluable pts) Response, n (%) y SCT pts Non-SCT pts Btz-based therapy n1⁄4235 n1⁄4412 ‡VGPR 152 (65) 163 (40)

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要